Drugs / Faropenem
Faropenem
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02393586 | Feb → Oct 2015 | tuberculosis | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02381470 | Feb → Sep 2019 | pulmonary tuberculosis | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 2 | NCT02349841 | Sep → Dec 2014 | pulmonary tuberculosis | TASK Applied Science | Completed | No outcome recorded |
| Phase 2 | NCT01886053 | Apr 2011 → Jul 2012 | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01937832 | Oct 2013 → Oct 2015 | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06804096 | Feb → Sep 2025 overdue | bacterial pneumonia | Dr. Md. Alimur Reza | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Faropenem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02393586 ↗ |
| Known as | FAROPENEM SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL556262 ↗ |
| Known as | Fropenem | ChEMBL registry synonym — accepted as the source's own label CHEMBL556262 ↗ |
| Modality | Small molecule | “faropenem (an oral penem, closely related to the carbapenem class)” NCT02381470 ↗ |
| Route | Oral | “Faropenem 600mg will be administered orally 8-hourly” NCT02349841 ↗ |